Search Results
24 protocol(s) meet the specified criteria
Phase IB (Open-Label) / Phase II (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine with or without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

101278Not Open *
Preoperative Extended Chemotherapy versus Chemotherapy plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma

Pembrolizumab for the Treatment of Recurrent High-Grade Neuroendocrine Carcinoma

Multicenter, Phase I, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

Phase I Open-Label Trial of a Combination of Nivolumab and Bevacizumab in Patients with Advanced and/or Metastatic Hepatocellular Carcinoma

Randomized Phase III Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Phase I/II, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Solid Tumors (FIM)

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Phase IIA Study of ABC294640 in the Treatment of Patients with Advanced, Unresectable Intra-Hepatic, Perihilar, and Extra-Hepatic Cholangiocarcinoma

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients with Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-Line Setting (APPEASE)

Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated with Familial Adenomatous Polyposis

Phase I Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

International, Multicenter, Open-Label, Randomized, Phase III Study of BLU-285 versus Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Phase IB/II Study to Evaluate Safety and Clinical Activity of Avelumab in Combination with Binimetinib with or without Talazoparib in Patients with Locally Advanced or Metastatic RAS-Mutant Solid Tumors

Phase I/II Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations

Phase IB, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with Cisplatin plus Gemcitabine and PEGPH20 in Combination with Atezolizumab and Cisplatin plus Gemcitabine Compared with Cisplatin plus Gemcitabine in Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Phase II/III Trial of Neoadjuvant FOLFOX with Selective use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

81405Not Open *
Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

Phase IB Trial of a Combination of mFOLFIRI with MEK162 in Patients with Advanced KRAS Positive Metastatic Colorectal Cancers

Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors